These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 2145964

  • 1. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
    Stein RC, Dowsett M, Hedley A, Gazet JC, Ford HT, Coombes RC.
    Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
    [Abstract] [Full Text] [Related]

  • 2. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
    Dowsett M, Stein RC, Coombes RC.
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
    MacNeill FA, Jacobs S, Dowsett M, Lonning PE, Powles TJ.
    Cancer Chemother Pharmacol; 1995 Sep; 36(3):249-54. PubMed ID: 7781147
    [Abstract] [Full Text] [Related]

  • 6. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
    Nicholson RI, Walker KJ, Walker RF, Read GF, Turkes A, Robertson JF, Blamey RW.
    Horm Res; 1989 Sep; 32 Suppl 1():198-201. PubMed ID: 2533149
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W.
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [Abstract] [Full Text] [Related]

  • 9. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB, Buzdar AU.
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [Abstract] [Full Text] [Related]

  • 10. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Jänicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK, Schmid H.
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [Abstract] [Full Text] [Related]

  • 11. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L, Martinetti A, Ferrari L, Buzzoni R, Mariani L, Miceli R, Seregni E, Procopio G, Cassata A, Bombardieri E, Bajetta E.
    Anticancer Res; 1999 Aug; 19(3B):2261-8. PubMed ID: 10472341
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex.
    Cassano A, Astone A, Garufi C, Noviello MR, Pietrantonio F, Barone C.
    Cancer Lett; 1989 Nov 30; 48(2):123-4. PubMed ID: 2555044
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
    Harris AL, Carmichael J, Cantwell BM, Dowsett M.
    Br J Cancer; 1989 Jan 30; 59(1):97-9. PubMed ID: 2527049
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
    Cheung KL, Agrawal A, Folkerd E, Dowsett M, Robertson JF, Winterbottom L.
    Eur J Cancer; 2010 Nov 30; 46(16):2936-42. PubMed ID: 20832294
    [Abstract] [Full Text] [Related]

  • 19. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
    Dowsett M, Doody D, Miall S, Howes A, English J, Coombes RC.
    Breast Cancer Res Treat; 1999 Jul 30; 56(1):25-34. PubMed ID: 10517340
    [Abstract] [Full Text] [Related]

  • 20. Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer.
    Gazet JC, Coombes RC, Ford HT, Griffin M, Corbishley C, Makinde V, Lowndes S, Quilliam J, Sutcliffe R.
    Br J Cancer; 1996 Mar 30; 73(6):758-62. PubMed ID: 8611376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.